TSBX - Turnstone Biologics Corp Debt to Book Capitalization Ratio

The historical trend of the debt-to-book capitalization ratio, where the latest reading is 0.03, is based on the delegation of clinical trials to external CRO centers. Turnstone Biologics (TSBX) seeks pricing power in oncology through unique TIL lymphocyte selection. A team of viral platform experts is retained on staff due to scientific freedom and ownership of company shares.

Summary analytical data breakdowns for turnstonebio.com (TSBX)

- price and consensus price forecast:

Stock Price Turnstone Biologics Corp.|TSBX - Consensus Target

- market capitalization data:

Market Value Turnstone Biologics Corp.|TSBX - Total Enterprise Value

- book capitalization data:

Net Assets per Single Share Turnstone Biologics|TSBX - Company Book Value|Market Value to Book Value Ratio turnstonebio.com|TSBX - Company Assets

- debt and liquidity data:

Total Debt to Capital Turnstone Biologics|TSBX - Long-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio Turnstone Biologics Corp.|TSBX - Company Cumulative Debt|Debt to Book Value Turnstone Biologics Corp.|TSBX - Company Long-Term Loans and Borrowings|Company Short-Term Debts Turnstone Biologics

Analysis of all company metrics:TSBX, Turnstone Biologics Corporation

Selecting stocks with a high margin of fundamental strength begins with an analysis of the debt load. The `dvsbcap_co` ratio measures the ability of equity to cover all liabilities, determining financial stability or the degree of leverage. For Turnstone Biologics (TSBX), this balance is critical when financing the development of TIL therapy against solid tumors. An optimal resource ratio ensures the advancement of innovation without the risk of bankruptcy. This price action reflects the capital structure trend: debt to book capitalization.

Competitors of Turnstone Biologics